DE3852773D1 - Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen. - Google Patents

Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.

Info

Publication number
DE3852773D1
DE3852773D1 DE3852773T DE3852773T DE3852773D1 DE 3852773 D1 DE3852773 D1 DE 3852773D1 DE 3852773 T DE3852773 T DE 3852773T DE 3852773 T DE3852773 T DE 3852773T DE 3852773 D1 DE3852773 D1 DE 3852773D1
Authority
DE
Germany
Prior art keywords
gastrointestinal disorders
methods
compositions
treatment
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE3852773T
Other languages
English (en)
Other versions
DE3852773T2 (de
Inventor
Geoffrey Place
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3852773(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of DE3852773D1 publication Critical patent/DE3852773D1/de
Application granted granted Critical
Publication of DE3852773T2 publication Critical patent/DE3852773T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE3852773T 1987-03-09 1988-03-02 Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen. Revoked DE3852773T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2359687A 1987-03-09 1987-03-09

Publications (2)

Publication Number Publication Date
DE3852773D1 true DE3852773D1 (de) 1995-03-02
DE3852773T2 DE3852773T2 (de) 1995-07-06

Family

ID=21816098

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3852773T Revoked DE3852773T2 (de) 1987-03-09 1988-03-02 Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.

Country Status (13)

Country Link
US (1) US5407688A (de)
EP (2) EP0578965A1 (de)
JP (1) JP2648328B2 (de)
KR (1) KR970007188B1 (de)
AT (1) ATE117206T1 (de)
AU (2) AU621285B2 (de)
CA (1) CA1312012C (de)
DE (1) DE3852773T2 (de)
DK (1) DK175866B1 (de)
IE (2) IE950632L (de)
IL (1) IL85472A (de)
NZ (1) NZ223774A (de)
ZA (1) ZA881678B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
CH679582A5 (de) * 1988-07-18 1992-03-13 Glaxo Group Ltd
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
EP0403048A3 (de) * 1989-06-14 1991-01-30 Warner-Lambert Company Medizinische Sucralfat enthaltende Zusammensetzungen und Verfahren zur Herstellung
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
ES2084174T3 (es) * 1990-07-20 1996-05-01 Tillotts Pharma Ag Productos y procesos para el tratamiento del conducto alimentario.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
DE59109225D1 (de) * 1990-09-14 2002-01-17 Byk Gulden Lomberg Chem Fab Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
IL105155A (en) * 1992-04-24 1999-05-09 Astra Ab Synergistic combination of an inhibitor of gastric acid secretion with an acid-breaking antibiotic
JPH08506353A (ja) * 1993-06-15 1996-07-09 フアイザー・インコーポレイテツド ウシもしくはブタの細菌感染における免疫刺激剤としてのｈ２−拮抗剤
WO1996014068A1 (de) * 1994-11-07 1996-05-17 Asche Ag Arzneimittel zur behandlung von erkrankungen des magen-darm-traktes
JP3042890B2 (ja) * 1994-11-21 2000-05-22 ファイザー製薬株式会社 フタリド化合物及びその製法
JP3767831B2 (ja) * 1995-06-14 2006-04-19 木村 健 ヘリコバクター・ピロリ除菌用組成物
CA2237384A1 (en) * 1995-11-13 1997-05-22 The Albany Medical College Analgesic compounds and uses thereof
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
CA2349575A1 (en) 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
ATE531361T1 (de) 2004-05-07 2011-11-15 Nycomed Gmbh Neue pharmazeutische dosierform und herstellungsverfahren
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
JP2011178722A (ja) * 2010-03-01 2011-09-15 Synmosa Biopharma Corp ヘリコバクタ−・ピロリ（Ｈ．ｐｙｌｏｒｉ）を除菌する医薬組成物及びその製造方法
EP2601947A1 (de) * 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2218883B1 (de) * 1973-02-28 1976-08-13 Science Union & Cie
US4333922A (en) * 1974-09-12 1982-06-08 Herschler R J Method for the treatment of water-living animals with health modifying agents
CH638975A5 (fr) * 1979-07-27 1983-10-31 Prebuilt Ets Composition medicamenteuse pour le traitement des ulceres gastro-duodenaux.
AU590578B2 (en) * 1985-04-18 1989-11-09 Procter & Gamble Company, The Treatment of non-ulcer dyspepsia with bismuth salts
EP0206626B2 (de) * 1985-06-13 2002-05-22 Barry James Dr. Marshall Verwendung von Bismuth zur Herstellung von Medikamenten zur Behandlung von Magen-Darmstörungen, die von Campylobacter polyridis verursacht sind
ATE318144T1 (de) * 1985-06-13 2006-03-15 Barry James Marshall Pharmazeutische zusammensetzung zur behandlung gastrointestinaler beschwerden, die wismut und ein antimikrobielles mittel enthält
US4959384A (en) * 1985-10-24 1990-09-25 Norwich Eaton Pharmaceuticals, Inc. Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
CH679582A5 (de) * 1988-07-18 1992-03-13 Glaxo Group Ltd
DE3830616A1 (de) * 1988-09-09 1990-03-15 Ruetgerswerke Ag Prophylaktikum fuer fische

Also Published As

Publication number Publication date
ZA881678B (en) 1988-09-07
EP0282131A2 (de) 1988-09-14
KR880011197A (ko) 1988-10-27
KR970007188B1 (ko) 1997-05-07
AU621285B2 (en) 1992-03-12
IE66367B1 (en) 1995-12-27
AU1030292A (en) 1992-03-05
DK127788A (da) 1988-09-10
DK175866B1 (da) 2005-04-18
JPS63290831A (ja) 1988-11-28
US5407688A (en) 1995-04-18
JP2648328B2 (ja) 1997-08-27
CA1312012C (en) 1992-12-29
EP0578965A1 (de) 1994-01-19
DK127788D0 (da) 1988-03-09
NZ223774A (en) 1991-02-26
IE880665L (en) 1988-09-09
IL85472A (en) 1991-06-30
DE3852773T2 (de) 1995-07-06
EP0282131B1 (de) 1995-01-18
IE950632L (en) 1988-09-09
EP0282131A3 (en) 1989-11-15
ATE117206T1 (de) 1995-02-15
AU660645B2 (en) 1995-07-06
AU1279388A (en) 1988-09-08

Similar Documents

Publication Publication Date Title
DE3852773D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Magen-Darmstörungen.
ATE81011T1 (de) Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
DE69009684D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler Störungen.
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE69328186D1 (de) Zusammensetzung zur behandlung der parkinson-krankheit
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
DE3750979D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung in der Behandlung neurodegenerativer Beschwerden.
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DE69622005D1 (de) Zusammensetzung zur Vorbeugung und Behandlung von urogenitalen Störungen, die Wismut und eine oder mehrere antimikrobielle Mitteln enthalten
DE3875637D1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
DE3162277D1 (en) N-(4-phenyl-2-thiazolyl)-oxamidic-acid-2-ethoxyethylester, process for its preparation and pharmaceutical compositions containing this compound
DE3775278D1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
ZA871140B (en) Synergistic chemical compositions for treating salmonellosis
NO982635L (no) Sammensetninger inneholdende vismut og ett eller flere antimikrobielle midler for forebygging og behandling av gastrointestinale forstyrrelser
DE69618813D1 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
DE69619542D1 (de) Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
ATE232736T1 (de) Zusammensetzungen zur vorbeugung und behandlung von urogenitalen störungen, die wismut enthalten
UA12753A (uk) Спосіб лікуваhhя та профілактики респіраторhих захворюваhь молодhяка сільськогосподарських твариh змішаhої етіології
ATE59529T1 (de) Antimikrobielles mittel zur behandlung von bauwerken, baustoffen, textilien, leder, agrarprodukten und/oder nahrungsmitteln.
DE3887137D1 (de) Mittel zur prophylaxe und behandlung einer pankreatischen erkrannkung oder dergleichen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation